Category: Markets
Published: 2026-08-17T16:40:50.000Z
Lexaria Bioscience Corp. (NASDAQ: LEXX) has regained compliance with Nasdaq's minimum bid price requirement, removing the immediate risk of delisting. Nasdaq confirmed Lexaria's compliance on August 17, 2026, leading to the cancellation of a previously scheduled hearing. As a result, Lexaria's common stock will continue to be listed and traded on The Nasdaq Capital Market.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.